🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

No difference in outcomes between MUD vs alternative graft sources Patients lacking MUD donor should not delay BMT and go ahead with alternative donor BMT #Tandem25 Abstract by Stephanie Lee

Autologous or allogeneic hematopoietic stem cell transplantation as front-line treatment for adult secondary acute myeloid leukemia patients: the PETHEMA registry experience Transplantation and Cellular Therapy Journal astctjournal.org/article/S2666-…

⭐ Multiple Myeloma spotlight: Latest survival and efficacy data from the phase III DREAMM-7 trial ⭐ During #ASH24, VaniaHungria shared the latest data from DREAMM-7 (NCT04246047), highlighting the early survival benefit associated with BVd. #myeloma #mmsm #MultipleMyeloma

Large Japanese study (n=7,499): Haplo-HCT with PTCy vs. single UCBT (Harada et al., TCT, 2025). Key takeaway: UCBT with low CD34+ (<0.84 × 10⁵/kg) had worse outcomes, while UCBT with high CD34+ (≥0.84 × 10⁵/kg) had similar NRM and OS to PTCy-haplo. #BMT #HaploHSCT #UCBT

Hot Off the Press 🚨🚨🚨ENHANCE-2- Randomized P3 Study of Aza/Magrolimab vs Physician Choice in Newly Dx TP53-mut AML- published in Blood Journal. We desperately need novel Tx’s for TP53 mut AML, disappointing results but critical info for future studies. ashpublications.org/blood/article/…

Venetoclax and Decitabine vs Intensive Chemotherapy as Induction for Young Patients with Newly Diagnosed AML ashpublications.org/blood/article/… 👉 Venetoclax plus decitabine NOT INFERIOR to intensive chemo in young fit AML. 👉VEN+DEC was well tolerated. #lesum #AML

The BALANCE trial demonstrated that a 7-day antibiotic treatment strategy is non-inferior to a 14-day strategy for hospitalized patients with bloodstream infections. Limitation in context of HCT: Pts with severe immunosuppression were excluded nejm.org/doi/full/10.10…

#Myeloma Paper of the Day: CASSIOPEIA #MRD data show dara maintenance improved MRD-negative rates vs. observation regardless of induction/consol. or risk status; D-VTd -> dara produced highest landmark, accumulative & sustained MRD-negativity & PFS: pubmed.ncbi.nlm.nih.gov/40127397/. #mmsm

Check out our comprehensive review on #AML from an MD Anderson Cancer Center perspective, " Therapeutic horizon of acute myeloid leukemia: Success, optimism, and challenges" published in ACS Journal Cancer acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn… #leusm

These are the 25 most cited papers published in the twenty-first century go.nature.com/4cIcWob

How I approach hematopoietic stem cell transplantation for CML in a TKI world Blood Journal ashpublications.org/blood/article/…

ICYMI: FDA panel votes 6-2 in favor of daratumumab for high-risk smoldering multiple myeloma sohoinsider.com/news/fda-panel…